Abstract:
인간의 모노사이트 또는 호중구에서 수퍼옥사이드 생성의 유도하거나; 인간 말초혈 모노사이트 또는 호중구에 의한 세포내 칼슘 증가를 유도하거나; FPR(formyl peptide receptor) 또는 FPRL1(formyl peptide receptor-like 1)에 결합하거나; 시험관내에서 인간의 모노사이트 또는 호중구의 주화성 이동을 유도하거나; FPR(formyl peptide receptor) 발현 세포 또는 FPRL1(formyl peptide receptor-like 1) 발현 세포에서 탈과립화을 유도히가나; FPR(formyl peptide receptor) 또는 FPRL1(formyl peptide receptor-like 1)의 활성화를 통하여 세포외 신호-조절된 단백질 카이나제 포스포릴레이션을 증가시키거나; FPR(formyl peptide receptor) 또는 FPRL1(formyl peptide receptor-like 1)의 활성화를 통하여 Akt 포스포릴레이션을 증가시키는 서열번호: 1 내지 24 의 펩타이드에 관한 것이다. 펩타이드, FPR, FPRL1, 주화성이동, 탈과립화, 포스포릴레이션, 칼슘가동화
Abstract:
PURPOSE: A pharmaceutical formulation for respiratory administration for treating or preventing respiratory inflammation disease is provided to suppress respiratory inflammation. CONSTITUTION: A pharmaceutical formulation for respiratory administration for treating or preventing respiratory inflammation diseases contains pharmaceutically or veterinarily acceptable carrier, peptide which functions in formyl peptide receptor(FPR) or analogous receptor thereof or pharmaceutically acceptable salt. The peptide comprises an amino acid sequence selected from sequence numbers 1-28. The carrier is vapor, liquid or microparticle powder.
Abstract:
A novel immune controlling peptide is provided to be used for selective immuno-modulators or selective antagonists for specific receptors, as well as screen of molecular diversity. The peptide comprises an amino acid sequence described as SEQ ID NO : 1 and has at least one property selected from the group consisting of: (a) inducing superoxide generation by human monocytes or neutrophils; (b) inducing anintracellular calcium increase by human peripheral blood monocytes or neutrophils; (c) binding to formyl peptide receptor or formyl peptide receptor-like 1; (d) inducing chemotactic migration of human monocytes or neutrophils in vitro; (e) inducing degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; (f) stimulating extracellular signal-regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; and (g) stimulating Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.